Company patents
Institut National de la Santé et de la Recherche Médicale (INSERM)
Institut National de la Santé et de la Recherche Médicale (INSERM) surprisingly shows a strong, albeit fluctuating, focus on "Pharmaceutical Preparations" (72.3% of its portfolio) and "Therapeutic Activity (Pharma)" (51.1%), with the latter experiencing a significant 33.3% YoY growth in 2024 before a slight decline in 2025. While its core pharma-biotech categories remain dominant, the rapid decline in "Peptides & Proteins" (down 100.0% so far in 2026) and "Heterocyclic Compounds (Pharma)" (down 100.0% so far in 2026) suggests a shifting priority within its drug discovery efforts, despite a 50.0% YoY growth in Heterocyclic Compounds in 2025.
Patent Trend by Technology Area
Yearly patent publications since 2023
Product themes
Product-level themes inferred from filings since 2023, with category chips showing where each theme appears. Select a theme to filter the patents below.
47 US filings (since 2023) · 12 categories · 19 themes
Development of therapeutic approaches involving the genetic modification of cells (e.g., T cells, stem cells, macrophages) or the use of viral/non-viral vectors to deliver genetic material for disease treatment.
Therapeutic approaches involving the use of living cells, often genetically modified or ex vivo activated, to treat diseases, particularly cancer, by modulating immune responses or replacing damaged cells.
Therapeutic strategies employing nucleic acids (DNA, RNA, oligonucleotides) to modulate gene expression, deliver genetic material, or interfere with disease-causing pathways. Includes gene therapy using viral vectors.
Design and synthesis of acyclic or carbocyclic organic compounds that selectively modulate specific biological targets or pathways for the treatment of diseases.
Development of small molecules, often bifunctional (e.g., PROTACs) or molecular glues, that induce the ubiquitin-proteasome system or autophagy to selectively degrade specific disease-causing proteins.
Methods and compositions for identifying, quantifying, or characterizing specific biological molecules (e.g., nucleic acids, proteins, metabolites, antibodies) or microbial species, often for diagnostic, prognostic, or quality control applications.
Development and application of therapeutic proteins or peptides produced through recombinant DNA technology, including fusion proteins and modified growth factors.
Delivery systems specifically engineered to administer advanced drug formulations (e.g., microparticles, biologics, extended-release systems) to achieve precise targeting, controlled release kinetics, or enhanced therapeutic efficacy within the body.
Utilizing machine learning, particularly deep learning, to analyze medical data such as images, sensor readings, or physiological signals for disease prediction, diagnosis, or treatment assessment.
Design and modification of antibodies or antibody-derived fragments for targeted therapeutic intervention, including bispecific formats, Fc region modifications, and activatable constructs.
Systems and methods that use imaging technologies, computer vision, and augmented reality to provide real-time guidance, localization, and visualization during surgical procedures or for detailed anatomical assessment.
Systems and methods for non-invasive or minimally invasive collection and analysis of physiological data (e.g., blood pressure, electrolytes, genetic markers, B cell repertoire) to assess patient health status, screen for conditions, or aid in diagnosis.
Therapeutic interventions that target immune checkpoint pathways to either enhance or suppress immune responses, often used in cancer immunotherapy or autoimmune diseases.
Methods and apparatus for detecting objects and determining their three-dimensional position and orientation (pose) using imagery or point cloud data, often for navigation, surveying, or environmental understanding.
Design and application of devices that are inserted into the body or implanted to treat diseases, modulate physiological functions, or repair anatomical structures.
Design and engineering of proteins or peptides to directly modulate immune responses, including enhancing antigen presentation, suppressing inflammation, or activating specific immune cell types.
Modification of protein or peptide sequences, structures, or post-translational modifications (e.g., glycosylation, lipidation) to enhance their stability, solubility, delivery, or therapeutic efficacy.
Development and application of polymer compositions designed for reprocessability, recyclability, or incorporating sustainable additives, often featuring reversible bonds or bio-based components.
Methods for synthesizing polyurethanes and polyureas, including non-isocyanate routes, using various monomers, catalysts, and curing agents, often for foams, coatings, or adhesives.
Patents
Showing 1-10 of 80